Cargando…
Natural killer cell-based immunotherapy for acute myeloid leukemia
Despite considerable progress has been achieved in the treatment of acute myeloid leukemia over the past decades, relapse remains a major problem. Novel therapeutic options aimed at attaining minimal residual disease-negative complete remission are expected to reduce the incidence of relapse and pro...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720594/ https://www.ncbi.nlm.nih.gov/pubmed/33287858 http://dx.doi.org/10.1186/s13045-020-00996-x |
_version_ | 1783619881319530496 |
---|---|
author | Xu, Jing Niu, Ting |
author_facet | Xu, Jing Niu, Ting |
author_sort | Xu, Jing |
collection | PubMed |
description | Despite considerable progress has been achieved in the treatment of acute myeloid leukemia over the past decades, relapse remains a major problem. Novel therapeutic options aimed at attaining minimal residual disease-negative complete remission are expected to reduce the incidence of relapse and prolong survival. Natural killer cell-based immunotherapy is put forward as an option to tackle the unmet clinical needs. There have been an increasing number of therapeutic dimensions ranging from adoptive NK cell transfer, chimeric antigen receptor-modified NK cells, antibodies, cytokines to immunomodulatory drugs. In this review, we will summarize different forms of NK cell-based immunotherapy for AML based on preclinical investigations and clinical trials. |
format | Online Article Text |
id | pubmed-7720594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77205942020-12-07 Natural killer cell-based immunotherapy for acute myeloid leukemia Xu, Jing Niu, Ting J Hematol Oncol Review Despite considerable progress has been achieved in the treatment of acute myeloid leukemia over the past decades, relapse remains a major problem. Novel therapeutic options aimed at attaining minimal residual disease-negative complete remission are expected to reduce the incidence of relapse and prolong survival. Natural killer cell-based immunotherapy is put forward as an option to tackle the unmet clinical needs. There have been an increasing number of therapeutic dimensions ranging from adoptive NK cell transfer, chimeric antigen receptor-modified NK cells, antibodies, cytokines to immunomodulatory drugs. In this review, we will summarize different forms of NK cell-based immunotherapy for AML based on preclinical investigations and clinical trials. BioMed Central 2020-12-07 /pmc/articles/PMC7720594/ /pubmed/33287858 http://dx.doi.org/10.1186/s13045-020-00996-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Xu, Jing Niu, Ting Natural killer cell-based immunotherapy for acute myeloid leukemia |
title | Natural killer cell-based immunotherapy for acute myeloid leukemia |
title_full | Natural killer cell-based immunotherapy for acute myeloid leukemia |
title_fullStr | Natural killer cell-based immunotherapy for acute myeloid leukemia |
title_full_unstemmed | Natural killer cell-based immunotherapy for acute myeloid leukemia |
title_short | Natural killer cell-based immunotherapy for acute myeloid leukemia |
title_sort | natural killer cell-based immunotherapy for acute myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720594/ https://www.ncbi.nlm.nih.gov/pubmed/33287858 http://dx.doi.org/10.1186/s13045-020-00996-x |
work_keys_str_mv | AT xujing naturalkillercellbasedimmunotherapyforacutemyeloidleukemia AT niuting naturalkillercellbasedimmunotherapyforacutemyeloidleukemia |